Prevalence of human papillomavirus types in cervical intraepithelial lesions;Infekuotumas atskirų žmogaus papilomos tipų virusais esant intraepitelinių gimdos kaklelio pokyčių

Medicina

Volumn 46, Issue 9, 2010, Pages 616-623

  Gudlevičiene, Živile ^a   Šepetiene, Agne ^a   Didžiapetriene, Janina ^a   Valuckas, Konstantinas Povilas ^a   Smailyte, Giedre ^a   Drasutiene, Gražina ^a   Nadišauskiene, Ruta Jolanta ^b  

^a VILNIUS UNIVERSITY   (Lithuania)

^b LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

Cervical intraepithelial lesions; Prevalence of human papillomavirus types

Indexed keywords

ARTICLE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; ISOLATION AND PURIFICATION; LITHUANIA; PAPILLOMAVIRUS INFECTION; PREVALENCE; UTERINE CERVIX CARCINOMA IN SITU; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LITHUANIA; PAPILLOMAVIRUS INFECTIONS; PREVALENCE;

EID: 78751611455     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina46090087     Document Type: Article

References (33)

1. Castellsague X, de Sanjose S, Aguado T, Louie KS, Bruni L, Munoz J, et al. HPV and cervical cancer in the world. 2007 Report. Vaccine 2007;25(Suppl 3):C1-26.
2. Lietuvos vėžio registras. (Lithuanian Can Registry.) Available from: URL: http://www.vuoi.lt/index.php?1146970586.
3. Hoory T, Monie A, Gravitt P, Wu TC. Molecular epidemiology of human papillomavirus. J Formos Med Assoc 2008;107(3): 198-217.
4. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004;68(2):362-72.
5. Monsonego J, Bosch FX, Coursaget P, Cox JT, Franco E, Frazer I, et al. Cervical cancer control, priorities and new directions [EUROGIN 2003 conclusions]. Int J Cancer 2004; 108(3):329-33.
6. Bosch FX, Burchell AN, Schiffman M, Giuliano MR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(Suppl 10): K1-16.
7. Medeiros LR, Hilgert JB, Zanini RR, Berwanger O, Bozzetti MC, Mylius LC. Vertical transmission of human papillomavirus: a systematic quantitive review. Cad Saude Publica 2005; 21(4):1006-15.
8. Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol 2006;Suppl:40470.
9. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM; ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007;195(11):1582-9.
10. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005;97(14):1066-71.
11. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97(14):1072-9.
12. Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12(2):186-92.
13. Al-Nafussi AI, Hughes DE. Histological features of CIN3 and their value in predicting invasive microinvasive squamous carcinoma. J Clin Pathol 1994;47(9):799-804.
14. Gravitt PE, Coutlée F, Iftner T, Sellors JW, Quint WG, Wheeler CM. New technologies in cervical cancer screening. Vaccine 2008;26(Suppl 10):K42-52.
15. Irenge LM, Robert A, Gala JL. Quantitative assessment of human β-globin gene expression in vitro by TaqMan realtime reverse transcription-PCR: comparison with competitive reverse transcription-PCR and application to mutations or deletions in noncoding regions. Clin Chem 2005;51:2395-6.
16. Manual for multiplex-PCR System for the screening of human papilloma virus (HPV). Available from: URL: http://www.seegene.co.kr/en/download/manual1_hpv4ace.pdf.
17. IARC Monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses. Vol. 90. Lyon: World Health Organization International Agency for Research on Cancer; 2007.
18. Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008;110(3 Suppl 2):S4-7.
19. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7(7): 453-9.
20. Clifford GM, Gallus S, Herrero R, Muńoz N, Snijders PJ, Vaccarella S, et al.; IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366(9490):991-8.
21. Kliučinskas M, Nadišauskienė RJ, Padaiga Ž, Špukaitė T. Žmogaus papiloma viruso paplitimas tarp 18-35 metu{ogonek} Kauno moteru{ogonek}. (Prevalence of human papillomavirus among 18-35-year-old Kaunas women.) Lietuvos akušerija ir ginekologija 1999;2(1):19-22.
22. Kliucinskas M,, Minkauskiene M. Prevalence and risk factors of HPV infection among high-risk rural and urban Lithuanian women. Gynecol Obstet Invest 2006;62(3):173-80.
23. Gudlevičienė Ž, Didžiapetrienė J, Sužiedėlis K, Lapkauskaitė L. Žmogaus papilomos viruso, jo tipu{ogonek} ir variantu{ogonek} tyrimai. (Investigation of human papillomavirus, its types and variants.) Medicina (Kaunas) 2005;41(11):910-5.
24. Gudlevičienė Ž, Ramael M, Didžiapetrienė J, Uleckienė S, Valuckas KP. Human papillomavirus and p53 polymorphism in Lithuanian cervical carcinoma patients. Oncology Gynecology 2006;102:530-3.
25. Maucort-Boulch D, Franceschi S, Plummer M; IARC HPV Prevalence surveys study group. International correlation between human papillomavirus prevalence and cervical cancer incidence. Cancer Epidemiol Biomarkers Prev 2008;17(3): 717-20.
26. Myers E, Huh WK, Wright JD, Smith JS. The current and future role of screening in the era of HPV vaccination. Gynecol Oncol 2008;109(Suppl 2):S31-9.
27. Wright TC, Van Damme P, Schmitt HJ, Meheus A. Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine 2006;24(Suppl 3):S3/122-31.
28. Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008;26(Suppl 10): K53-61.
29. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119(11):2677-84.
30. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121(3):621-32.
31. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89(1): 101-5.
32. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26(Suppl 10): K29-41.
33. Hildesheim A, Hadjimichael O, Schwartz PE, Wheeler CM, Barnes W, Lowell DM, et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol 1999;180(3 Pt 1):571-7.